European Urology Open Science最新文献

筛选
英文 中文
Editorial on the Abstracts from the 22nd Meeting of the Association of Academic European Urologists (AAEU)
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-04-03 DOI: 10.1016/j.euros.2025.01.007
John Heesakkers (Secretary General), Frans Debruyne (Honorary Communications Officer), Christopher Chapple (22nd AAEU Meeting President)
{"title":"Editorial on the Abstracts from the 22nd Meeting of the Association of Academic European Urologists (AAEU)","authors":"John Heesakkers (Secretary General), Frans Debruyne (Honorary Communications Officer), Christopher Chapple (22nd AAEU Meeting President)","doi":"10.1016/j.euros.2025.01.007","DOIUrl":"10.1016/j.euros.2025.01.007","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Page 43"},"PeriodicalIF":3.2,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Factors for Pregnancy and Patency Rates After Microsurgery for Obstruction of the Upper Seminal Tract: A Retrospective Single-surgeon Series of 336 Cases
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-04-01 DOI: 10.1016/j.euros.2024.08.010
Marco A. Sieber , Jan Blaser , Roland Seiler , Dominik Abt , Jennifer Blarer , Adrian Sieber
{"title":"Prognostic Factors for Pregnancy and Patency Rates After Microsurgery for Obstruction of the Upper Seminal Tract: A Retrospective Single-surgeon Series of 336 Cases","authors":"Marco A. Sieber ,&nbsp;Jan Blaser ,&nbsp;Roland Seiler ,&nbsp;Dominik Abt ,&nbsp;Jennifer Blarer ,&nbsp;Adrian Sieber","doi":"10.1016/j.euros.2024.08.010","DOIUrl":"10.1016/j.euros.2024.08.010","url":null,"abstract":"<div><h3>Background and objective</h3><div>To achieve optimal results in treating vasal obstruction, microsurgery is the standard of care. However, not all vasovasostomy (VV) or vasoepididymostomy (VE) procedures lead to subsequent pregnancy. Identification of parameters that can predict success in restoring fertility is clinically relevant. We evaluated various parameters in relation to patency and pregnancy outcomes in a retrospective single-surgeon series.</div></div><div><h3>Methods</h3><div>We analysed data for 336 men with azoospermia due to vasal obstruction who underwent microsurgery to restore fertility. Seminal fluid was harvested intraoperatively from the testicular stump for analysis of gross quality. Intraoperative parameters, time to conception, patency rate, age of the female partner, and time from vasectomy to reconstruction were assessed in relation to pregnancy outcomes. Multivariable logistic regression was performed to identify independent prognostic parameters.</div></div><div><h3>Key findings and limitations</h3><div>The median age at surgery was 42 (range 27–70) yr for the men and 33 (range 19–46) yr for their female partners. The overall patency rate after surgery was 86.8% (236/272). Secondary obstruction occurred in 14/272 men (5.1%). Pregnancy was achieved in 127/258 couples (49.2%). The most significant predictor of successful treatment was the obstruction time (<em>p</em> &lt; 0.01), with significantly lower success rates for longer times since vasectomy. None of the intraoperative parameters we analysed was associated with subsequent pregnancy. The primary limitation of our study is its retrospective design.</div></div><div><h3>Conclusions and clinical implications</h3><div>Patency and pregnancy rates in our series are similar to rates reported in the literature. Pregnancy success after vasectomy reversal mainly depends on the time since vasectomy. Additional biomarkers are needed to predict postoperative pregnancy outcomes.</div></div><div><h3>Patient summary</h3><div>In our study, nearly 87% of men were fertile again after surgery to reverse a vasectomy, and about half of the couples were then able to get pregnant. The key factor for success was the time since vasectomy, with better results for shorter times. More research is needed to find reliable ways to predict if a couple will get pregnant after this surgery.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 37-42"},"PeriodicalIF":3.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends for Surgical Treatment of Testicular Varicocele: A German Whole-population Analysis of Inpatient Procedures from 2006 to 2021
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-28 DOI: 10.1016/j.euros.2025.03.001
Cem Aksoy , Philipp Reimold , Philipp Karschuck , Subhajit Mandal , Nicole Eisenmenger , Christer Groeben , Aristeidis Zacharis , Johannes Huber , Luka Flegar
{"title":"Trends for Surgical Treatment of Testicular Varicocele: A German Whole-population Analysis of Inpatient Procedures from 2006 to 2021","authors":"Cem Aksoy ,&nbsp;Philipp Reimold ,&nbsp;Philipp Karschuck ,&nbsp;Subhajit Mandal ,&nbsp;Nicole Eisenmenger ,&nbsp;Christer Groeben ,&nbsp;Aristeidis Zacharis ,&nbsp;Johannes Huber ,&nbsp;Luka Flegar","doi":"10.1016/j.euros.2025.03.001","DOIUrl":"10.1016/j.euros.2025.03.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>Testicular varicocele (TVC) is a common benign finding in men of all ages. Indications for TVC repair are abnormal sperm parameters and testicular pain. The optimal surgical method for TVC repair is still a matter of controversy. The aim of our study was to analyze the current situation and trends for TVC surgery in Germany.</div></div><div><h3>Methods</h3><div>The German reports for hospital quality were analyzed from 2006 to 2021. Linear regression models were applied to detect trends over time. Outpatient procedure rates were estimated.</div></div><div><h3>Key findings and limitations</h3><div>A total of 38 653 inpatient TVC surgeries were included. Total varicocelectomy procedures decreased from 3456 in 2006 to 2165 in 2021 (−37.4%; <em>p</em> &lt; 0.001). The proportion of open TVC procedures remained constant at ∼25%. The proportion of laparoscopic TVC procedures increased from 25% in 2006 to 45% in 2021 (<em>p</em> &lt; 0.001), while the sclerotherapy rate for TVC treatment decreased from 47% in 2006 to 29% in 2021 (<em>p</em> &lt; 0.001). In 2006, 543 hospitals offered TVC treatment, which decreased to 466 hospitals in 2021 (−14.2%). Among patients undergoing surgical TVC procedures in 2021, 75% were younger than 35 yr. We estimated an increase in outpatient procedures from 365 cases in 2013 to 1330 cases in 2021 (<em>p</em> &lt; 0.001). The estimation for outpatient procedures represents a study limitation.</div></div><div><h3>Conclusions and clinical implications</h3><div>Laparoscopic TVC treatment is the dominant surgical approach. However, one in three patients receives sclerotherapy for TVC in Germany. While fewer hospitals offer the treatment, we observed a trend for centralization, with an increase in high-caseload departments, as well as an increasing trend for outpatient treatment.</div></div><div><h3>Patient summary</h3><div>TVC is a collection of swollen veins in the testicle. We analyzed treatment trends in Germany for this condition from 2006 to 2021. There was an increase in the use of keyhole surgery over time, and we estimate that the percentage of day-case surgeries also increased.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 29-36"},"PeriodicalIF":3.2,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing Screening Performance for the Risk of Hyperoxaluria and Urolithiasis Using the Urinary Oxalate/Creatinine Ratio: A Retrospective Analysis
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-28 DOI: 10.1016/j.euros.2025.03.003
Pierre Letourneau , Lara Cabezas , Aurélie De Mul , Nadia Abid , Christelle Machon , Cécile Poussineau , Cécile Acquaviva , Justine Bacchetta , Laurence Derain-Dubourg , Sandrine Lemoine
{"title":"Optimizing Screening Performance for the Risk of Hyperoxaluria and Urolithiasis Using the Urinary Oxalate/Creatinine Ratio: A Retrospective Analysis","authors":"Pierre Letourneau ,&nbsp;Lara Cabezas ,&nbsp;Aurélie De Mul ,&nbsp;Nadia Abid ,&nbsp;Christelle Machon ,&nbsp;Cécile Poussineau ,&nbsp;Cécile Acquaviva ,&nbsp;Justine Bacchetta ,&nbsp;Laurence Derain-Dubourg ,&nbsp;Sandrine Lemoine","doi":"10.1016/j.euros.2025.03.003","DOIUrl":"10.1016/j.euros.2025.03.003","url":null,"abstract":"<div><h3>Background and objective</h3><div>The risk of chronic kidney disease (CKD) and nephrolithiasis increases with higher levels of oxalate excretion in 24-h urine, warranting monitoring in specific populations, especially after malabsorptive bariatric surgery. However, implementation of systematic 24-h urine collection is challenging, so there is a need for alternative screening methods.</div></div><div><h3>Methods</h3><div>Using retrospective data from patients evaluated for the risk of urolithiasis, we assessed different thresholds for the urinary oxalate/creatinine (UOx/Creat) ratio to optimize the screening performance for hyperoxaluria diagnosis and urolithiasis risk using lithogenic risk surrogates.</div></div><div><h3>Key findings and limitations</h3><div>Among 1264 patients referred for urolithiasis, 38% were excluded because urine collection was considered incomplete. The remaining 786 individuals were included in our analysis, of whom 16% exhibited hyperoxaluria. A UOx/Creat screening threshold between 35 and 45 μmol/mmol demonstrated good performance, depending on the clinical weighting for false-negative versus true-positive results and the cost/benefit ratio.</div></div><div><h3>Conclusions and clinical implications</h3><div>The UOx/Creat ratio is a promising tool in screening for hyperoxaluria-related complications. However, future research is needed to validate its performance and address the limitations identified to confirm its clinical relevance and effectiveness.</div></div><div><h3>Patient summary</h3><div>Our study shows that a simple test to measure the ratio of oxalate to creatinine in urine can help in identifying people at risk of kidney stones, especially for patients who have had weight-loss surgery. The test showed good screening performance, but more research is needed to confirm our findings.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 20-28"},"PeriodicalIF":3.2,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-26 DOI: 10.1016/j.euros.2025.02.005
Yuzhi Wang , Samantha Wilder , Monica Van Til , Mackenzie Gammons , Mahin Mirza , Sabrina L. Noyes , Mohammad Jafri , Brian Seifman , Khurshid R. Ghani , Alice Semerjian , Craig G. Rogers , Brian R. Lane , for the Michigan Urological Surgery Improvement Collaborative
{"title":"Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative","authors":"Yuzhi Wang ,&nbsp;Samantha Wilder ,&nbsp;Monica Van Til ,&nbsp;Mackenzie Gammons ,&nbsp;Mahin Mirza ,&nbsp;Sabrina L. Noyes ,&nbsp;Mohammad Jafri ,&nbsp;Brian Seifman ,&nbsp;Khurshid R. Ghani ,&nbsp;Alice Semerjian ,&nbsp;Craig G. Rogers ,&nbsp;Brian R. Lane ,&nbsp;for the Michigan Urological Surgery Improvement Collaborative","doi":"10.1016/j.euros.2025.02.005","DOIUrl":"10.1016/j.euros.2025.02.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>In Michigan, around 50% of patients with localized renal masses of ≤7 cm (cT1RMs) are managed without immediate intervention, contradicting previous reports indicating active surveillance (AS) rates of &lt;10–20%. Questions remain regarding the durability of AS when applied so broadly. We evaluated the oncologic outcomes of patients at 1, 2, and 3 yr after the initiation of AS, including survival and delayed intervention rates, hypothesizing that these will be comparable to prior reports.</div></div><div><h3>Methods</h3><div>Between May 2017 and September 2023, data regarding 2161 (52% of 4178) patients with cT1RMs who initiated AS at Michigan Urological Surgery Improvement Collaborative (MUSIC) practices were reviewed. Factors associated with staying on AS were analyzed. Overall survival and the cumulative incidence of treatment were assessed using the Kaplan-Meier method.</div></div><div><h3>Key findings and limitations</h3><div>In total, 2161 patients from 21 practices initiated AS, including 51% with tumors of ≤2 cm, 26% with tumors of 2.1–3.0 cm, and 24% with tumors of 3.1–7.0 cm. At 36 mo, overall survival was 90%, with metastasis and death from kidney cancer in only one patient who refused intervention. The cumulative incidence rates of treatment were 6%, 11%, and 13% at 1, 2, and 3 yr, respectively, with 9.6% for ≤2 cm, 16% for 2.1–3.0 cm, and 18% for &gt;3 cm tumors at 3 yr. Limitations include the study’s retrospective review of prospectively enrolled data limiting conclusions beyond 3 yr of follow-up.</div></div><div><h3>Conclusions and clinical implications</h3><div>MUSIC practices initiate AS for &gt;50% of patients with 13% incidence of delayed intervention and &lt;1% incidence of metastasis within 3 yr, indicating that AS is a safe and durable option for many patients with cT1RMs. Further investigations into imaging protocols and longer-term outcomes of AS are warranted.</div></div><div><h3>Patient summary</h3><div>In Michigan, most patients diagnosed with localized renal masses of &lt;4 cm and some with tumors up to 7 cm in size elect active surveillance (AS), with a 13% cumulative incidence of undergoing intervention within 3 yr of detection. At 3 yr after initiating AS, the cohort had 90% overall survival and &gt;99% cancer-specific survival, indicating that AS is a safe and durable strategy.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 11-19"},"PeriodicalIF":3.2,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Copyright page
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-25 DOI: 10.1016/S2666-1683(25)00090-4
{"title":"Copyright page","authors":"","doi":"10.1016/S2666-1683(25)00090-4","DOIUrl":"10.1016/S2666-1683(25)00090-4","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"74 ","pages":"Page I"},"PeriodicalIF":3.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of Small Renal Masses <2 cm: Treatment
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-25 DOI: 10.1016/j.euros.2023.12.010
Andrea Minervini , Antonio Andrea Grosso , Fabrizio Di Maida
{"title":"Management of Small Renal Masses <2 cm: Treatment","authors":"Andrea Minervini ,&nbsp;Antonio Andrea Grosso ,&nbsp;Fabrizio Di Maida","doi":"10.1016/j.euros.2023.12.010","DOIUrl":"10.1016/j.euros.2023.12.010","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"74 ","pages":"Pages 73-74"},"PeriodicalIF":3.2,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-21 DOI: 10.1016/j.euros.2025.02.008
Lisa J. Kroon , Ivo I. de Vos , Charlotte F. Kweldam , Monique J. Roobol , Geert J.L.H. van Leenders , Roderick C.N. van den Bergh , Anser Prostate Cancer Network
{"title":"Targeted Prostate Biopsies Overestimate International Society of Urological Pathology Grade Group, Particularly in Smaller Tumors","authors":"Lisa J. Kroon ,&nbsp;Ivo I. de Vos ,&nbsp;Charlotte F. Kweldam ,&nbsp;Monique J. Roobol ,&nbsp;Geert J.L.H. van Leenders ,&nbsp;Roderick C.N. van den Bergh ,&nbsp;Anser Prostate Cancer Network","doi":"10.1016/j.euros.2025.02.008","DOIUrl":"10.1016/j.euros.2025.02.008","url":null,"abstract":"<div><div>Compared with systematic biopsy of the prostate, magnetic resonance imaging (MRI)-targeted biopsies are associated with lower rates of upgrading and higher rates of downgrading between biopsy tissue and radical prostatectomy (RP) specimen International Society of Urological Pathology (ISUP) grade group (GG). Higher rates of downgrading could indicate overtreatment for some patients. We hypothesized that concordance rates between biopsy and RP are different per MRI tumor volume. We conducted an explorative retrospective study to identify the risk factors for downgrading, using RP specimens as the reference standard, in a large regional prostate collaboration. Among 616 patients, pathological concordance was seen in 58% and downgrading in 15%. The risk of downgrading was 18% for tumors of 0–10 mm, 14% for 10–20 mm, and 14% for &gt;20 mm. In a multivariable analysis among patients with targeted biopsy GG ≥2, with covariates including clinical tumor stage, prostate-specific antigen (PSA), maximal MRI index lesion diameter, number of positive target biopsies, and GG at targeted biopsy, the statistically significant predictors for downgrading were PSA, maximum MRI index lesion diameter, and target biopsy GG. A lower risk of downgrading was seen in larger tumors (odds ratio per millimeter 0.95, 95% confidence interval 0.91–1.00, <em>p</em> = 0.033). This study suggests that an overestimation of GG on biopsy is most common in smaller MRI lesions. This information is important in clinical decision-making, mainly in deciding on active surveillance versus active therapy or the indication for additional imaging for cancer staging.</div></div><div><h3>Patient summary</h3><div>In this report, we examined risk factors that could explain why some patients have higher pathological grading at prostate biopsy than on the whole prostate specimen after surgical removal. We found that patients with prostate biopsies that are targeted at small lesions on magnetic resonance imaging and patients who had high biopsy grading had a higher risk of having lower grading of their surgical specimens.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 7-10"},"PeriodicalIF":3.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Antiaggregant and Anticoagulant Medications on Perioperative Complications in Upper Tract Urothelial Carcinoma
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-20 DOI: 10.1016/j.euros.2025.02.007
Kang Liu , Chris Ho-Ming Wong , Hongda Zhao , Chi Fai Ng , Jeremy Yuen-Chun Teoh , Pilar Laguna , Jean de la Rosette
{"title":"Impact of Antiaggregant and Anticoagulant Medications on Perioperative Complications in Upper Tract Urothelial Carcinoma","authors":"Kang Liu ,&nbsp;Chris Ho-Ming Wong ,&nbsp;Hongda Zhao ,&nbsp;Chi Fai Ng ,&nbsp;Jeremy Yuen-Chun Teoh ,&nbsp;Pilar Laguna ,&nbsp;Jean de la Rosette","doi":"10.1016/j.euros.2025.02.007","DOIUrl":"10.1016/j.euros.2025.02.007","url":null,"abstract":"<div><h3>Background and objective</h3><div>Contemporary data are limited regarding the clinical practice of administering anticoagulant and antiplatelet medications (AA) perioperatively for patients with upper tract urothelial carcinoma (UTUC). Our aim was to investigate real-world AA perioperative management among patients with UTUC who underwent radical nephroureterectomy (RNU) and the impact on perioperative complications.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of data from the Clinical Research Office of the Endourology Society UTUC registry. Patients were stratified into two groups according to perioperative AA use in the RNU cohort. Baseline characteristics were compared between the control and AA groups and intraoperative and postoperative complications were analyzed. We also conducted subgroup analysis for patients who discontinued AA use in comparison to those who continued AA therapy. Univariable and multivariable analyses were performed to identify predictors of perioperative complications.</div></div><div><h3>Key findings and limitations</h3><div>A total of 1264 patients who underwent RNU were included in the analysis. Of these, 393 (31%) had AA treatment before RNU and 871 (69%) did not. Intraoperative complications occurred in 23 patients (5.9%) in the AA group and 41 (4.7%) in the control group. Postoperative complications occurred in 101 patients (26%) in the AA group and 182 (21%) in the control group. Multivariable logistic regression demonstrated that AA was not an independent risk factor for either intraoperative complications (odds ratio 0.93, 95% confidence interval [CI] 0.48–1.83; <em>p</em> = 0.84) or postoperative complications (odds ratio 0.93, 95% CI 0.66–1.30; <em>p</em> = 0.66).</div></div><div><h3>Conclusions and clinical implications</h3><div>Anticoagulant and antiaggregant therapy in patients undergoing RNU is safe, with no difference in the incidence of intraoperative and postoperative complications.</div></div><div><h3>Patient summary</h3><div>Our analysis for patients with cancer in the upper urinary tract showed that taking drugs to prevent blood clots before surgery to remove a kidney is safe. We found no significant differences in complication rates in comparison to patients not taking these drugs.</div><div>The Clinical Research Office of the Endourology Society UTUC registry study is registered on ClinicalTrials.gov as NCT02281188.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"75 ","pages":"Pages 1-6"},"PeriodicalIF":3.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative, Oncological, and Functional Outcomes of New Multiport Robotic Platforms in Urology: A Systematic Review and Meta-analysis
IF 3.2 3区 医学
European Urology Open Science Pub Date : 2025-03-03 DOI: 10.1016/j.euros.2025.02.003
Giuseppe Reitano , Arianna Tumminello , Umar Ghaffar , Giorgio Saggionetto , Alessandra Taverna , Francesco Mangiacavallo , Mohamed E. Ahmed , Spyridon P. Basourakos , Filippo Carletti , Davide Minardi , Massimo Iafrate , Alessandro Morlacco , Giovanni Betto , R. Jeffrey Karnes , Fabrizio Dal Moro , Fabio Zattoni , Giacomo Novara
{"title":"Perioperative, Oncological, and Functional Outcomes of New Multiport Robotic Platforms in Urology: A Systematic Review and Meta-analysis","authors":"Giuseppe Reitano ,&nbsp;Arianna Tumminello ,&nbsp;Umar Ghaffar ,&nbsp;Giorgio Saggionetto ,&nbsp;Alessandra Taverna ,&nbsp;Francesco Mangiacavallo ,&nbsp;Mohamed E. Ahmed ,&nbsp;Spyridon P. Basourakos ,&nbsp;Filippo Carletti ,&nbsp;Davide Minardi ,&nbsp;Massimo Iafrate ,&nbsp;Alessandro Morlacco ,&nbsp;Giovanni Betto ,&nbsp;R. Jeffrey Karnes ,&nbsp;Fabrizio Dal Moro ,&nbsp;Fabio Zattoni ,&nbsp;Giacomo Novara","doi":"10.1016/j.euros.2025.02.003","DOIUrl":"10.1016/j.euros.2025.02.003","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and objective&lt;/h3&gt;&lt;div&gt;Robot-assisted surgery (RAS) has steadily become more prevalent in urology. The Da Vinci multiport surgical robot (DVM-SR) continues to lead the field. In recent years, new multiport surgical robots (NM-SRs) have been introduced to the market; however, their safety and efficacy remain unassessed. This study aims to give a comprehensive evaluation of the perioperative, oncological, and functional outcomes of NM-SRs and a comparison with the DVM-SR.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A systematic search was performed in PubMed, Scopus, Web of Science, Embase, and clinicaltrial.gov to identify studies that evaluate NM-SRs in major urological surgeries assessing perioperative, functional, and oncological endpoints. A meta-analysis was performed comparing NM-SRs with the DVM-SR for safety, and functional and oncological outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Key findings and limitations&lt;/h3&gt;&lt;div&gt;Seventy-four studies involving 5487 patients were included in the review. Nine platforms were studied: Hinotori, Hugo RAS, Revo-I, Versius, Avatera, Senhance, KangDuo Surgical Robot-01, Dexter, and Toumai. NM-SRs were used to perform robot-assisted radical prostatectomy (RARP; 41 studies), partial nephrectomy (RAPN; 14 studies), radical nephrectomy (RARN; four studies), adrenalectomy (four studies), nephroureterectomy (two studies), RARN and thrombectomy (one study), colpopexy (four studies), pyeloplasty (seven studies), simple nephrectomy (four studies), simple prostatectomy (three studies), and ureteral surgery (four studies). Cystectomies with NM-SRs were described only in case reports and were excluded. The comparative analysis between NM-SRs and the DVM-SR showed similar outcomes in terms of intraoperative SATAVA grade ≥2 complications (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.25, 3.1, &lt;em&gt;p&lt;/em&gt; = 0.9 for RARP and OR 0.59, 95% CI 0.11, 3.3, &lt;em&gt;p&lt;/em&gt; = 0.5 for RAPN), postoperative high-grade complications (Clavien-Dindo ≥IIIa, OR 0.85, 95% CI 0.4, 2, &lt;em&gt;p&lt;/em&gt; = 0.7 for RARP and OR 0.59, 95% CI 0.1, 3.3, &lt;em&gt;p&lt;/em&gt; = 0.6 for RAPN), and positive surgical margins (OR 0.90, 95% CI 0.72, 1.1, &lt;em&gt;p&lt;/em&gt; = 0.3 for RARP and OR 1.65, 95% CI 0.3, 9.1, &lt;em&gt;p&lt;/em&gt; = 0.6 for RAPN). For patients undergoing RARP, biochemical recurrence and urinary continence rates at 3 mo were comparable (OR 0.99 [95% CI 0.5, 1.8, &lt;em&gt;p&lt;/em&gt; = 1] and OR 0.99 [95% CI 0.77, 1.3, &lt;em&gt;p&lt;/em&gt; = 0.9], respectively). The achievement of the trifecta for RAPN appeared to be similar between the included studies on NM-SRs and the DVM-SR (OR 1.3, 95% CI 0.4, 4.4, &lt;em&gt;p&lt;/em&gt; = 0.7). The small sample size of the included studies and the preliminary nature of the results represent the major limitations.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions and clinical implications&lt;/h3&gt;&lt;div&gt;When compared with the DVM-SR, NM-SRs may offer similar safety, and oncological and functional outcomes across most surgeries for both benign and malignant diseases. Further research ","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"74 ","pages":"Pages 44-70"},"PeriodicalIF":3.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信